CMA levies fines of £2.3m in pharma probe
The fines are in addition to £8 million secured for the NHS last year as part of the case
Read More
Tag: Aspen
Aspen to pay NHS £8m after CMS probe
The offer hopes to resolve competition concerns over the supply of a fludrocortisone acetate 0.1 mg tablets.
Read More
Aspen Pharmacare hit by EU antitrust cancer drug price probe
European regulators will investigate pricing of five oncology treatments
Read More
GSK sells non-core assets to Aspen
GlaxoSmithKline is selling its portfolio of anaesthetics and thrombosis business to Aspen as it continues to simplify its business strategy through focusing on core therapeutic areas.
Read More
AZ sells anaesthetics portfolio to Aspen
AstraZeneca is selling rights to its global anaesthetics portfolio outside the US to Aspen Global Inc (AGI) in a deal that could be worth $770 million.
Read More
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
- Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
